IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: PHARMACEUTICAL DRUGS

Lyon, 17–24 October 1989

LIST OF PARTICIPANTS

Members

I.N. Chernozemsky, National Oncological Centre, Medical Academy, Darvenitza, Sofia 1156, Bulgaria

L. Fiore-Donati, Istituto di Anatomia e Istologia Patologica, Verona University, Policlinico Borgo Roma, 37100 Verona, Italy

G.D. Friedman, Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, 3451 Piedmont Avenue, Oakland, CA 94611, USA

B. Holmberg, Department of Toxicology, National Institute of Occupational Health, 171 84 Solna, Sweden

L.J. Kinlen, Cancer Research Campaign Epidemiology Unit, University of Edinburgh, 15 George Square, Edinburgh EH8 9JZ, UK

M. Marselos, Department of Pharmacology, Medical School, University of Ioannina, Ioannina 45110, Greece

M. Mattila, Department of Clinical Pharmacology, University of Helsinki, Department of Clinical Pharmacology, University of Helsinki, Paasikivenkatu 4, 00250 Helsinki, Finland

G. Obe, Universität GSH Essen, Fachbereich 9, Department of Genetics, PO Box 103 764, 4300 Essen 1, Federal Republic of Germany

J.H. Olsen, Danish Cancer Registry, Rosenvaengets Hovedvej 35, Box 839, 2100 Copenhagen Ø, Denmark

N.V. Popova, Laboratory of Carcinogenic Substances, All-Union Cancer Research Centre, Kashirskoye Shosse 24, 115478 Moscow, USSR
J.P. Seiler1, Swiss Federal Research Station for Fruit-Growing, Viticulture and Horticulture, 8820 Wädenswil, Switzerland
S. Shapiro, Boston University Medical School, Slone Epidemiology Unit, 1371 Beacon Street, Brookline, MA 02146, USA
S.M. Sieber, Division of Cancer Etiology, National Cancer Institute, Building 31, Room 11A03, Bethesda, MD 20892, USA
M. Sorsa, Institute of Occupational Health, Topeliuksenkatu 41 a A, 00250 Helsinki, Finland (Vice-Chairperson)
R. Stahlmann, Institut für Toxikologie und Embryonal Pharmakologie der Freien Universität Berlin, Gagystrasse 1-9, 100 Berlin 33, Federal Republic of Germany
B. Stewart, Children’s Leukaemia and Cancer Research Unit, The Prince of Wales Children’s Hospital, High Street, Randwick, NSW 2031, Australia
F.M. Sullivan, Department of Pharmacology, Guy’s Hospital Medical School, London SE1 9RT, UK
J. Weissinger, Office of Drug Evaluation (HFD-502), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA
G.M. Williams, American Health Foundation, Dana Road, Valhalla, NY 10595, USA (Chairman)
K. Yokoro, Hiroshima University, Institute of Nuclear Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan

Representatives and observers2

Representative of the International Federation of Pharmaceutical Manufacturers’ Associations
E. Longstaff, Safety Medicines Department, ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

Representative of the US Pharmaceutical Manufacturers’ Association
M.J. Tidd, Norwich Eaton Pharmaceuticals Inc., PO Box 191, Norwich, NY 13815-0191, USA

1Present address: Interkantonale Kontrollstelle für Heilmittel (IKS), Erlachstrasse 8, 3000 Bern, Switzerland
2Unable to attend, M.-Th. van der Venne, Commission of the European Communities, Health and Safety Directorate, Bâtiment Jean Monnet (C4/83), BP 1907, 2920 Luxembourg, Grand Duchy of Luxembourg
PARTICIPANTS

Secretariat

A. Aitio, Laboratory of Biochemistry, Institute of Occupational Health, Arinatie 3, 00370 Helsinki, Finland
H. Bartsch, Unit of Environmental Carcinogenesis and Host Factors
X. Bosch, Unit of Field Intervention Studies
E. Cardis, Unit of Biostatistical Research and Informatics
J. Cheney, Editorial, Translation and Publication Services
M. Coleman, Unit of Descriptive Epidemiology
M. Friesen, Unit of Environmental Carcinogenesis and Host Factors
E. Heseltine, Montignac, France
J. Jongen, Unit of Mechanisms of Carcinogenesis
J. Kaldor, Unit of Biostatistics Research and Informatics
V. Krutovskikh, Unit of Mechanisms of Carcinogenesis
K. L'Abbé, Unit of Analytical Epidemiology
D. McGregor, Unit of Carcinogen Identification and Evaluation
D. Mietton, Unit of Carcinogen Identification and Evaluation
R. Montesano, Unit of Mechanisms of Carcinogenesis
S. Narod, Unit of Mechanisms of Carcinogenesis
G. Nordberg, Unit of Carcinogen Identification and Evaluation
C. Partensky, Unit of Carcinogen Identification and Evaluation
I. Peterschmitt, Unit of Carcinogen Identification and Evaluation, Geneva, Switzerland
D. Shuker, Unit of Environmental Carcinogenesis and Host Factors
L. Shuker, Unit of Carcinogen Identification and Evaluation
L. Tomatis, Director
H. Vainio, Unit of Carcinogen Identification and Evaluation
J. Wilbourn, Unit of Carcinogen Identification and Evaluation

Secretariat assistance

J. Cazaux
M. Lézère
S. Reynaud